Review Article
The Effect of Terpenoid Natural Chinese Medicine Molecular Compound on Lung Cancer Treatment

Heng Sun, Lijia Zhang, Bowen Sui, Yu Li, Jun Yan, Peng Wang, Ye Wang, and Songjiang Liu

1 The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Department of Oncology, Harbin, China
2 Heilongjiang University of Chinese Medicine, Harbin, China
3 The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Department of Oncology Ethics Office, Harbin, China
4 The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Department of Oncology Respiratory, Harbin, China
5 The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Academic Affairs Section, Harbin, China

Correspondence should be addressed to Songjiang Liu; liusongjiang@hljucm.net

Received 3 November 2021; Revised 18 November 2021; Accepted 1 December 2021; Published 16 December 2021

Academic Editor: Ruchika Garg

Copyright © 2021 Heng Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Among all malignant tumors in the whole universe, the incidence and mortality of lung cancer disease rank first. Especially in the past few years, the occurrence of lung cancer in the urban population has continued to increase, which seriously threatens the lives and health of people. Among the many treatments for lung cancer, chemotherapy is the best one, but traditional chemotherapy has low specificity and drug resistance. To address the above issue, this study reviews the five biological pathways that common terpenoid compounds in medicinal plants interfere with the occurrence and development of lung cancer: cell proliferation, cell apoptosis, cell autophagy, cell invasion, metastasis, and immune mechanism regulation. In addition, the mechanism of the terpenoid natural traditional Chinese medicine monomer compound combined with Western medicine in the multipathway antilung cancer is summarized.

1. Introduction

The latest research has shown that lung cancer is the most common form of the malignant tumor whose morbidity and mortality have increased year by year in recent years. It has become the major cause of death due to cancer around the globe [1, 2]. According to the latest report, in 2018, approximately 18.1 million people worldwide were affected by different types of cancer. Among them, the number of deaths caused by lung cancer is about 2.1 million [3]. There has been advanced technology operated to treat lung cancer named as targeted therapy. The earliest targeted drugs used in clinics are mainly targeted at the epidermal growth factor and its receptor (EGF-EGFR) pathway, tyrosine kinase inhibitor, anti-VEGF monoclonal antibody, and VEGFR tyrosine kinase inhibitor (VEGFR-TKI) [4]. Since the beginning of 2000, multitarget drugs have rapidly developed [5]. Crizotinib is an ALK inhibitor, but it also targets LTK, CHEK2, FLT3, PHKG2, and RET. Nintedanib and sorafenib are multiple tyrosine kinase inhibitors targeting FGFR, PDGFR, and VEGFR [6]. Among them, gefitinib (Iressa) and erlotinib (trocet) are the most commonly used inhibitors. They are epidermal growth factor receptor inhibitors. Still, because of their selectivity for patients with gene mutations and the ease of medication, the occurrence of drug resistance has become the bottleneck of its widespread application [7, 8]. In the year 2020, there are a total of 89 small molecule targeted antitumor drugs that were approved by the American FDA and China’s NMPA. These small molecule targeted at anticancer drugs are still at the challenging phase where they face drug resistance and low response rates [9].

Many active ingredients derived from herbal medicines of China have anticancer properties that include anti-proliferative, proapoptotic, antimitastatic, and...
antiangiogenic effects [10]. These active ingredients can target the gene targets of the malignant proliferation of tumor cells, selectively induce tumor cell apoptosis without affecting normal cells, provide new research strategies for tumor treatment, and improve the treatment results of patients with NSCLC. New research emerges, including terpenoids, flavonoids, polyphenols, polysaccharides, and alkaloids. [11]. Among them, terpenoids are natural products derived from mevalonic acid (mevalonic acid, MVA). Terpenoids are composed of multiple isoprene (isoprene, C5) structural units, and the general formula is (C5H8)n, which is also the most common compound among natural products. It is present in a large quantity in the plant kingdom and has a large variety of styles. It has the potential to be a lead compound to develop efficient and new and safe antitumor drugs. At present, terpenoids with antitumor activity are classified into monoterpenes, sesquiterpenes, diterpenes, and triterpenes (Table 1).

In recent years, people have gradually realized that there are major effects of natural products on NSCLC, especially when it comes to improving anticancer activity and drug sensitivity. On the basis of this fact, the anticancer mechanism of natural small molecule compounds of terpenoid Chinese medicine on lung cancer has been summarized.

2. Cell Cycle Regulation and Inhibition of Tumor Cell Proliferation

An important feature of tumor cells is uncontrolled growth. The occurrence of tumors stems from changes in genetic material DNA (or genes), and this change is a multistep cellular process of multiple genetic changes. As mentioned above, cell cycle regulation is a delicate balance process, and any defects in this process may lead to changes in genetic information. The different phases of the cell cycle are highly accurately coordinated to ensure strict timing. For example, cyclins, CDK inhibitors, and other regulatory molecules need to be activated or degraded in time to ensure the regular operation of the cell cycle [12, 13]. In the course of normal cells into tumor cells, there may be cell cycle disorders, tumor cell invasion and metastasis, and drug insensitivity phenomenon [14]. Almost all tumors destroy the cell cycle regulation mechanism, leading to the characteristics of uncontrolled cell growth, blocked differentiation, and abnormal apoptosis [15]. In short, the destruction of the molecular regulation mechanism of the cell cycle, or the disorder of its upstream agent, will lead to an abnormal cell cycle. The following content is introduced, that is, the molecular mechanism of terpenoid natural TCM small molecules in treating lung cancer by inhibiting cell proliferation (Table 2).

Andrographolide (Andro) is the main active compound that is wholly spread in Andrographis paniculata, a kind of herb that is used as a natural remedy for various diseases [23, 24]. Studies have shown that Andro treatment can increase DNA fragmentation and reduce Na+ - K+ - ATPase activity, indicating α-subunit dysfunction and/or mitochondrial membrane damage, and also indicating mitochondrial dysfunction caused by AD, and reducing TGF-β1 and VEGF expression levels inhibits tumor cell proliferation and downregulates PCK to promote lung cancer cell apoptosis [16, 17].

The small molecule active substance of licorice is mainly glycyrrhizic acid with different chemical structure. Among them, there are many related types of research on glycyrrhizinic acid [25, 26]. Glycyrrhizic acid has various medicinal activities just like retinoic acid and steroids. Relevant studies have shown that 18β-GA can inhibit cell proliferation and induce NSCLC cell apoptosis at least in part [18, 19].

Glycyrrhetinic acid (GA) can inhibit cell lines of humans (A549 and NCI-H460), of which A549 is more sensitive than NCI-H460. Glycyrrhetinic acid activates p18/p16 to inactivate the CDK4/6-cyclin-D1/D3 complex. Glycyrrhetinic acid can activate p27/p21 to inactivate the CDK2-cyclin-E2 complex, thereby causing cell arrest in the G1 period. This condition can lead to the dephosphorylation of pRb in both cell types to regulate cell cycle progression and the inactivation of transcription factor 1 (E2F-1), a critical apoptotic transcription factor. GA is upregulated, and it has the ability to inhibit the proliferation of NSCLC cells via the emergency pathway of the endoplasmic reticulum. GA induces chaperones of ER, which reduces the synthesis of proteins [27].

Carnosic acid has various biological functions, which majorly include antibacterial, antioxidant, and anti-proliferative activities [20]. Different treatment concentrations of CA can inhibit the proliferation/G one and G 2/M phases of IMR-90 and NCI-H460 cells [28].

There are two subclasses of ginsenosides, namely, protoanxadiol (PPD) and protoanxatriol (PPT) [21]. Related research has synthesized 13 kinds of ginseng diol derivatives through amino acids. Compared with PD, ginseng diol derivatives 3, 12, and 13 have a significant effect of inhibition on the cell cycle of cancer cells. Among them, ginseng diol has the IC 50 value for A549 (IC 50 = 18.91 ± 1.03 microns) [19].

Astragaloside is the main active component of Astragalus, which is composed of many triterpene saponins, including astragaloside I-IV [29]. The study found that astragaloside IV if given in high dose can inhibit the growth of NSCLC cells (A549, HCC827, and NCI-H1299); while if it is present in low concentration, there will be no apparent cytotoxicity to the viability of the cell. In addition, astragaloside IV combined with medication majorly enhances the chemosensitivity of NSCLC cells [22].

3. Mechanisms of Inducing Apoptosis of Lung Cancer Cells

The process of apoptosis is a highly conservative suicide program of the cell. The body clears excess cells and dangerous cells through apoptosis to maintain homeostasis [30]. Inactivation of the apoptosis program can lead to the occurrence of autoimmune diseases and tumors. In cell cycle-monitoring point function inactivation, the obstruction of cell apoptosis can cause DNA damage to be carried into daughter cells, thereby increasing genome instability and causing cell malignancy [31]. Tumor cells can usually resist
apoptosis [32]. At present, the primary strategies for targeted tumor therapy include the following: (1) the expression of the proapoptotic gene p53 is restored [33]; (2) the anti-apoptotic gene Bcl-2 is inactivated [34]; (3) the sensitivity of tumor cell apoptosis is increased by regulating metabolism (Bax and Bak) [35]; and (4) biological therapy is related (antibody-directed therapy, immunotherapy, virus-based introduction of apoptosis-inducing factor p53, and proapoptotic miRNA) [36–38]. The following is introduced, that is, the molecular mechanism of terpenoid natural Chinese medicine small molecules to promote apoptosis of cancerous cells in the treatment of lung cancer (Table 3).

### Table 1: Part of terpenoids and category of traditional Chinese medicine (TCM) for lung cancer treatment.

<table>
<thead>
<tr>
<th>Category</th>
<th>For example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terpenoid natural TCM molecular compound</td>
<td>Monoterpene, sesquiterpene, diterpene, and triterpene</td>
</tr>
<tr>
<td>A single TCM</td>
<td>Andrographis, licorice, carnosic, ginseng, astragalus, atractylodes, aucklandia, pachymic, rhizoma bolbospermus, curcumol, tripterygium wilfordii, and bupleurum</td>
</tr>
<tr>
<td>TCM monomer</td>
<td>Andro, glycyrrhizic acid, glycyrrhetic acid, carnosic acid, ginsenosides, astragaloside, atractylodes macrocephala, costunolide, pachyic acid, polypronic acid, teubimoseide, ivy saponins, curcumol, oridonin, triptolide, luteol, betulinic acid, saikosaponin, and cucurbitacin</td>
</tr>
</tbody>
</table>

### Table 2: Molecular mechanism of terpenoid natural TCM small molecules in treating lung cancer by inhibiting cell proliferation.

<table>
<thead>
<tr>
<th>Terpenoid natural TCM small molecules</th>
<th>Experimental model</th>
<th>Dose/concentration</th>
<th>Mechanism of action</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrographolide (AD)</td>
<td>H3255 NSCLC cells</td>
<td>AD (1.0, 2.5, or 5.0 μM) for 24 h</td>
<td>Decreased in the na (+)-k (+)-ATPase activities; decreased VEGF and TGF-β1 level; inhibited protein kinase C activities in H3255 cells. Released lactate dehydrogenase. Increased DNA fragmentation level.</td>
<td>[16]</td>
</tr>
<tr>
<td>Andrographolide (AD)</td>
<td>H3255 NSCLC cells</td>
<td>AD (1, 5, or 10 μM) for 24, 48, or 72 h</td>
<td>Inhibited proliferation of H3255 cell; decrease in MMP-9 expression and activity. Decrease in cell proliferation induced by transfection with TxAS small-interfering RNA (siRNA); Inhibited TxAS and its initiated ERK/CREB signaling. Arrested cell cycle in G0/G1.; Inhibited (CKIs) (p18, p16, p27, and p21); Inhibited cyclins (cyclin-D1, cyclin-D3, and cyclin-E); Inhibited cyclin-dependent kinases (CDKs) (CDK4, CDK6, and CDK2).</td>
<td>[17]</td>
</tr>
<tr>
<td>18β-glycyrrhetinic acid (18β-GA)</td>
<td>A549, NCI-H460, and NCI-H23 NSCLC cells</td>
<td>18β-GA (80, 160, or 320 μM) for 24 h</td>
<td>Decrease in cell proliferation induced by transfection with TxAS small-interfering RNA (siRNA); Inhibited TxAS and its initiated ERK/CREB signaling. Arrested cell cycle in G0/G1.; Inhibited (CKIs) (p18, p16, p27, and p21); Inhibited cyclins (cyclin-D1, cyclin-D3, and cyclin-E); Inhibited cyclin-dependent kinases (CDKs) (CDK4, CDK6, and CDK2).</td>
<td>[18]</td>
</tr>
<tr>
<td>Glycyrrhetinic acid (GA)</td>
<td>A549 and NCI-H460 NSCLC cells</td>
<td>GA (50, 25, 12.5, 6.25 or 3.125 μmol/l) 24, 48, or 72 h</td>
<td>Arrested cell cycle in G0/G1.; Inhibited (CKIs) (p18, p16, p27, and p21); Inhibited cyclins (cyclin-D1, cyclin-D3, and cyclin-E); Inhibited cyclin-dependent kinases (CDKs) (CDK4, CDK6, and CDK2).</td>
<td>[19]</td>
</tr>
<tr>
<td>Carnosic acid (CA)</td>
<td>IMR-90 (human fetal lung fibroblasts) and NCI-H460 NSCLC cells</td>
<td>CA (40, 80, 160, 240, or 320 μM) 24 h</td>
<td>Arrest at G0/G1 and G2/M phases.</td>
<td>[20]</td>
</tr>
<tr>
<td>13 panaxadiol (PD)</td>
<td>HepG-2 (human hepatoma cells), A549 NSCLC cells, MCF-7 (human breast cancer cells), or HCT-116 (human colon cancer cells)</td>
<td>PD (IC50 = 8.62 ± 0.23 μM)</td>
<td>Inhibited cellular proliferation.</td>
<td>[21]</td>
</tr>
<tr>
<td>Astragaloside IV</td>
<td>A549, HCC827, NCI-H1299 NSCLC cells</td>
<td>Astragaloside IV high doses (10, 20, and 40 ng/ml) and low doses (1, 2.5, and 5 ng/ml)</td>
<td>Inhibited the mRNA and protein levels of B7-H3.</td>
<td>[22]</td>
</tr>
</tbody>
</table>
that ATL-I can effectively inhibit tumor growth in xenograft of mice by upregulating caspase-3 and caspase-9 [40].

Costunolide is known to be present in the germacrannolide series. It was first extracted from the roots of Saussurea lappa Clarke [47]. Costus lactone is mediated by stress, and exposure activates the (UPR) signaling pathway. In addition, costus lactone induces ROS production, while the antioxidant N-acetylcysteine (NAC) is effective. It blocked ER stress and apoptosis activation, induced A549 cell apoptosis, and showed antitumor activity [41]. Costus lactone involves in the activation of caspase-3 and induces SK-MES-1 cell apoptosis [42].

Pachydermic acid (PA) can simultaneously induce apoptosis of NCI-H23 and NCI-H460 lung cancer. In addition, PA inhibits the NCI-H23 growth and xenograft cancers with an inability to cause toxicity in the host cell, inhibits proliferation of cells in tumor xenograft tissues, induces tumor cell apoptosis, and can also induce A549 cell apoptosis and destroy mitochondrial membrane potential [43, 44].

Polyphonic acid C (PPAC) is a triterpene compound derived from Poria cocos. PPAC induces cell apoptosis via the death receptor. In addition, the inhibition of the PI3-kinase/Akt signaling pathway and the enhancement of p53 activation indicate that this is an extra process to induce apoptosis [45].

Tubeimoside I (TBMS1), also known as tubeimoside A, is a triterpenoid isolated from the Bolbostemma paniculatum plant [48]. Tubeimoside I also has the ability to initiate apoptosis of lung cancer cells and destruct lysosome and mitochondrial pathways. One of its mechanisms is to induce DRP1-mediated mitochondrial fragmentation. It also disrupts lysosomal acidification by inhibiting V-ATPase, thereby blocking late-stage autophagic flux; this leads to the accumulation of reactive oxygen species (ROS). Cathepsin B

### Table 3: The molecular mechanism of terpenoid natural Chinese medicine small molecules to promote tumor cell apoptosis in the treatment of lung cancer.

<table>
<thead>
<tr>
<th>Terpenoid natural TCM small molecules</th>
<th>Experimental model</th>
<th>Dose/concentration</th>
<th>Mechanism of action</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atractylodes macrocephala I (ATL-I)</td>
<td>A549 and HCC827 NSCLC cells</td>
<td>ATL-I (10, 20, and 40 µM) for 48 h</td>
<td>Upregulation of caspase-3, caspase-9, and Bax; Downregulation of Bcl-2 and Bcl-XL; Increased lactate dehydrogenase release; Modulated cell cycle on A549 cells; Induced the release of cytochrome c; Uptregulation of Bax expression</td>
<td>[39]</td>
</tr>
<tr>
<td>Atractylodes macrocephala III (ATL-III)</td>
<td>A549 NSCLC cells</td>
<td>ATL-II I (1–100 µM) for 24 h</td>
<td>Upregulation of GRP78 and IRE1α and the activation of ASK1 and JNK; Induced ROS generation;</td>
<td>[40]</td>
</tr>
<tr>
<td>Costunolide</td>
<td>A549 NSCLC cells</td>
<td>Costunolide (0, 5, 10, 15, 25, or 30 µM) for 24 h</td>
<td>Changed the antiapoptotic function of Bcl-2; Induced cell cycle arrest at G1/S phase; Uptregulation in the expression of p53 and Bax; Downregulation in the expression of Bcl-2 and activation of caspase-3; Induced cell cycle arrest at G2/M phase; Induced ROS generation;</td>
<td>[41]</td>
</tr>
<tr>
<td>Costunolide</td>
<td>SK-MES-1 human lung squamous carcinoma cells</td>
<td>Costunolide (40 and 80 µM) for 24 h</td>
<td>Activation of both c-Jun N-terminal kinase (JNK) and endoplasmic reticulum (ER) stress apoptotic pathways. Inhibited anchorage-dependent and anchorage-independent A549 growth; Induced apoptosis of A549 cells; Decreased IL-1 beta-induced activation of ePLA (2) and COX-2; Suppressed IL-1 beta-induced activation of MAPKs; Inhibited IL-1 beta-stimulated nuclear factor kappa B of NF-kB; Suppressed PI3-kinase/Akt signal pathway; Enhanced p53 activation.</td>
<td>[42]</td>
</tr>
<tr>
<td>Pachymic acid (PA)</td>
<td>NCI-H23 and NCI-H460 lung cancer cells</td>
<td>PA (20, 40, or 80 µM) for 24 h</td>
<td>Induction of DRP1-mediated mitochondrial fragmentation; Inhibited V-ATPase and blocked late-stage autophagic flux via; Blocked the removal of dysfunctional mitochondria; Induced ROS generation.</td>
<td>[43]</td>
</tr>
<tr>
<td>Pachymic acid (PA)</td>
<td>A549 NSCLC cells</td>
<td>PA (0, 3, 10, 30, 60, 100, and 200 µM) for 24 or 48 h</td>
<td>Suppressed PI3-kinase/Akt signal pathway; Enhanced p53 activation.</td>
<td>[44]</td>
</tr>
<tr>
<td>Polyporonic acid C (PPAC)</td>
<td>A549 NSCLC cells</td>
<td>PPAC (0, 2, 6, 20, 60, or 200 µM) for 24, 48, or 72 h</td>
<td>Suppression of PI3-kinase/Akt signal pathway; Induction of DRP1-mediated mitochondrial fragmentation; Inhibited V-ATPase and blocked late-stage autophagic flux via; Blocked the removal of dysfunctional mitochondria; Induced ROS generation.</td>
<td>[45]</td>
</tr>
<tr>
<td>Tubeimoside I (TBMS1)</td>
<td>NCI-H1299 and NCI-H1975 lung cancer cells</td>
<td>TBMS1 (0, 10, 20, and 30 µM) for 24 h</td>
<td></td>
<td>[46]</td>
</tr>
</tbody>
</table>
Evidence-Based Complementary and Alternative Medicine

5. Metastasis and Inhibition of Tumor Invasion

Metastasis linked with tumor invasion is a very complex phenomenon; multiple molecules affect tumor invasion-metastasis behavior from different aspects. Cell adhesion molecules are the key molecules to maintain the tissue structure, and they are also the main molecules that affect cell adhesion and motility [54]. The extracellular matrix is the tissue barrier for cancer cell invasion and metastasis. The enzymes responsible for degrading the extracellular matrix and their inhibitors are closely related to tumor metastasis [55]. Hepatocyte growth factor (HGF) and chemotactic factors are critical driving forces for tumor cell movement [56]. Promoting and inhibiting the balance between VEGF, PDGF, and TGF-β also directly affect the blood supply of tumors, which further affect metastasis [57–59]. An in-depth analysis of these various factors will help us more deeply understand the mechanism of tumor metastasis.

Curcumin is a kind of sesquiterpenoids with pharmacological activity, and it is an essential bioactive component mainly from plants of the genus Curcuma [60, 61]. Studies have been conducted to extract zedoary turmeric essential oil (EO-CZ) by steam distillation and to test the growth of cancerous metastasis in mice. The experimental results show that EO-CZ has effects of antiproliferation on B16BL6 and SMMC-7721 cells. MMP-7 is the smallest member of the metalloproteinase. Extracellular matrix and substrate together constitute the first barrier in tumor metastasis, and its degradation is tumor invasion, and it is the critical link of transfer [62].

Tumor cells can induce tumor lymphatic endothelial cell (LEC) proliferation and lymphangiogenesis by expressing VEGF-C and VEGF-D to increase the number of lymphatic vessels and promote tumors. Lymphatic metastasis of cells can also increase the permeability of lymphatic vessels and the pressure of tumor interstitium, which facilitates the entry of tumor cells into blood vessels [63, 64]. At the same time, LEC can express chemokines and interact with surrounding microenvironmental mediators [65]. It can attract tumor cells expressing the corresponding receptor and promote tumor lymph node metastasis [66]. Some studies have extracted ten compounds, including costanolactone, by chromatography using bioassay-guided fractionation methods, which can inhibit TR-LE cells [67].

Oridonin is a natural compound that derives from ent-karate tetracyclic diterpene. It is first extracted from Isodon as a species [68]. It has the ability to inhibit the proliferation of H1688 cells and induce their apoptosis under high-dose treatment (20 μmol/L). At the same time, oridonin (5 and 10 μmol/L) inhibits the FAK-ERK1/2 signaling pathway without affecting cell proliferation and apoptosis [69].

Triptolide (TP) is a natural compound that has been isolated from the root of TP. Triptolide can change the expression of microRNA being utilized in cell movement and reduce the invasion of lung cancer cells. Triptolide reduces the expression of cell adhesion molecules, which leads to impaired downstream signal transduction and inhibits the formation of metastatic tumors in lung cancer mice injected with H358 cells [70]. In addition, TP combined...
Tumors and prolonging survival [75]. Antitumor immune effect to achieve the purpose of treating the body's immune status and activate the body's antitumor immunity. Researchers, through the in-depth understanding of the body's antitumor immune mechanism, immune intervention on tumor patients, used various methods to reverse the body's antitumor immune mechanism, eventually causing tumors to occur and develop in the body and even inhibit the body's immune function. Researchers, through the in-depth understanding of the body's antitumor immune mechanism, immune intervention on tumor patients, used various methods to reverse the body's immune status and activate the body's antitumor immune effect to achieve the purpose of treating tumors and prolonging survival [75].

Astragaloside IV (AS-IV) has been shown to inhibit the Jak3/Stat3 pathway-dependent IDO activation triggered by IFN-γ, and it is achieved by direct binding to the Jak3 protein [76]. IDO is also known to act as a checkpoint molecule that combines with cytotoxic T-lymphocyte antigen-4 and programmed cell death-1 to cause T-cell suppression after tumor transformation, in order to be prevented by the immune system from initiating the attack on cancer [77]. Experiments prove that Astragaloside IV (AS-IV) inhibits tumor growth in vivo experiments [78]. Studies have found that lupeol inhibits the growth of THP-1 by inhibiting the production of plasminogen activator inhibitor-1 (PAI-1) in A549 cells. In addition, lupeol can inhibit the polarization of M2 macrophages and lead to the reduction in Lewis lung carcinoma (LLC) cell migration [79] (Figure 1).

6. Tumor-Immune Mechanism and Immunotherapy

The immune system is directly connected with the occurrence and formation of tumors in the body. The cancer antigens abnormally expressed by cells in the process of carcinogenesis are the core of tumor immunodiagnosis, and the body's various antitumor immune mechanisms are the theoretical basis for tumor immunotherapy. The body's antitumor mechanism is mainly based on cellular immune mechanisms. Different immune cells play an essential role in antitumor immunity. Antibodies' complements and cytotoxic molecules are also effective molecules of tumor immunity [74]. Although the body has an antitumor immune mechanism, tumor cells can also evade immune attack through various mechanisms, eventually causing tumors to occur and develop in the body and even inhibit the body's immune function. Researchers, through the in-depth understanding of the body's antitumor immune mechanism, immune intervention on tumor patients, used various methods to reverse the body's immune status and activate the body's antitumor immune effect to achieve the purpose of treating tumors and prolonging survival [75].

Astragaloside IV (AS-IV) has been shown to inhibit the Jak3/Stat3 pathway-dependent IDO activation triggered by IFN-γ, and it is achieved by direct binding to the Jak3 protein [76]. IDO is also known to act as a checkpoint molecule that combines with cytotoxic T-lymphocyte antigen-4 and programmed cell death-1 to cause T-cell suppression after tumor transformation, in order to be prevented by the immune system from initiating the attack on cancer [77]. Experiments prove that Astragaloside IV (AS-IV) inhibits tumor growth in vivo experiments [78]. Studies have found that lupeol inhibits the growth of THP-1 by inhibiting the production of plasminogen activator inhibitor-1 (PAI-1) in A549 cells. In addition, lupeol can inhibit the polarization of M2 macrophages and lead to the reduction in Lewis lung carcinoma (LLC) cell migration [79] (Figure 1).

7. Combination Medication and MultiChannel antitumor

The use of multiple combinations as combined drugs to selectively target cancer cells has brought hope to a new generation of therapies (Figure 2).

7.1. Betulinic Acid. Betulinic acid (BA) can be considered ideal in treating lung cancer, and it provides a new treatment strategy for combination therapy. Studies have shown that the combination of 3 drugs (BA, ERKi, and HCO) has a better therapeutic effect than a single treatment or therapy in xenotransplantation mouse models. Among them, betulinic acid, a natural compound, can inhibit cell proliferation and induce NSCLC cell apoptosis [80–84]. At the same time, the autophagy inhibition of hydroxycamphorquinone (HQC) increased the response of lung cancer cells to the combination of BA and ERKi [80]. In addition, studies have proposed that betulinic acid (BA) and dichloroacetic acid (DCA) are chemically modified to synthesize a new combination drug Bet-CA, and its in vitro studies revealed that Bet-CA has apparent synergistic cytotoxicity to a broad spectrum of cancer cells, increased the production of reactive oxygen species (ROS), and promoted cells to undergo mitochondrial-mediated apoptosis; in vivo studies of Bet-CA showed tumor inhibition potential, and the clinically achievable dose will not produce any apparent toxicity [85].

Studies have suggested that BA treatment can induce apoptosis of paclitaxel-resistant human lung cancer H460 cells. In addition, BA can downregulate the expression of...
Bcl-2 and upregulate the expression of Bcl-2-related X (Bax) [86]. Studies have also suggested that sorafenib combined with betulinic acid strongly induces apoptosis of different NSCLC cells. In addition, this combination is not toxic to human peripheral blood lymphocytes. Compared with using two compounds alone, sorafenib combined with betulinic acid can induce apoptosis on different NSCLC cells (A549, H358, and A427) and eliminate the clonogenic activity [87, 88]. In vitro studies have shown that if, honokiol, ginsenoside Rh2, and betulinic acid are present in

![Figure 1: The influence of ATL-III, AS-IV, and lupeol on the immune mechanism of lung cancer.](image-url)
combination, they exhibit synergistic effects. Compared with the combination therapy group, the cisplatin group has obvious renal damage, and the combination therapy and the combination drug liposome therapy are safer [89].

7.2. Saikosaponin D. Saikosaponin D is a saponin extract extracted from Bupleurum (Umbelliferae), which can induce apoptosis to inhibit the proliferation of A549 [90]. Studies suggest that saikosaponin D inhibits the proliferation of lung cancer cells A549 (IC50, 3.57 µM) and H1299 (IC50, 8.46 µM) [91].

Saikosaponin A and saikosaponin D are two natural compounds derived from Bupleurum. At present, the combined application of natural small molecule compounds and chemotherapeutic drugs has become a research hotspot. Relevant studies have explored whether saikosaponins can sensitize the cytotoxicity of tumor cells induced by cisplatin. The results show that saikosaponin can make tumor cells [92].

In addition, studies have shown that saikosaponin D (SSD) and (EGFR-TKIs) gefitinib have an enhanced antitumoral effect on NSCLC cells. It is related to the inhibition of the STAT3/Bcl-2 signaling pathway [93].

7.3. Cucurbitacin B. Cucurbitacin is a natural plant triterpenoid that belongs to the Cucurbitaceae. Cucurbitacin B (CuB) has antimitastatic, antiangiogenic, and antitumor immunity potential for NSCLC in vitro and in vivo [94, 95]. The expression of TPG and TSG can inhibit cell proliferation and induce apoptosis in NSCLC [96]. CUCs lead to the induction of programmed cell death, the inhibition of cell migration, and cell invasion. It can also regulate the expression of cyclin B1 to induce apoptosis and G2/M cell cycle arrest, thereby interfering with lung cancer metastasis [97, 98].

In the combined application of CuB and chemotherapeutics, the new semisynthetic derivatives of CuB (DACE) and three chemotherapeutic drugs, namely, cisplatin (CIS), irinotecan (IRI), and paclitaxel (PAC), can induce apoptosis in A549 cells. It regulates the cell cycle, has a synergistic antiproliferative effect, and does not reduce the proliferation of nontumor lung cells (MRC-5) [99]. In addition, the semisynthetic derivative of CuB, DACE (2-deoxy-2-aminocucurbitacin E), and paclitaxel (PTX) showed potential in vitro synergistic antiproliferative effects in A549 cells [99]. In addition, CuB can reduce the proliferation of gefitinib-resistant (GR) PC9 cell lines by regulating the miR-17-5p/STAT3 axis [100].

7.4. Ginsenoside. Ginsenosides are one of the main components of ginseng and belong to typical terpenoids. Ginsenoside Rg3 reduces vascular endothelial growth factor expression and increases the ratio of CD4/CD8 T cells [101, 102]. We found that ginsenoside metabolite K (CK) can significantly enhance the expression and activity of p53 in the two lung cancer cell lines H460 and A549 induced by cisplatin and cooperate with cisplatin to inhibit tumor cell proliferation and induce apoptosis [103]. It decreased the antiapoptotic protein Bcl-2, which significantly increased the cells of NSCLC cell lines. Apoptosis substantially reduces the migration of NSCLC cells [104]. The combination therapy of ginsenoside Rg3 and gemcitabine can dramatically reduce the expression of VEGF and
MVD, blood flow, and PSV signals in tumors, inhibit tumor growth, and prolong survival [105]. In addition, ginsenoside Rg18 can inhibit tumor cell proliferation by mediating G1 phase block and intracellular ROS production in A549 human NSCLC cells, and p38, JNK, and NF-κB/p65 [106, 107].

8. Discussion

In recent years, the application of small molecular compounds of natural Chinese medicine in antitumor research has gradually become a new focus of international cancer research. With the continuous in-depth analysis of the anticancer activity of natural Chinese medicines, many biologically active compounds derived from traditional Chinese medicines can be used to treat NSCLC. The role is gradually recognized. At present, plant-derived anticancer drugs account for about 32% of the total anticancer drugs, of which terpenoids account for a large proportion. Researchers use small molecular compounds of traditional Chinese medicine to influence the cell cycle, induce cell apoptosis, promote autophagy, inhibit tumor cell invasion and metastasis, improve tumor-immune microenvironment, and other ways to achieve tumor treatment and prolong patient survival. Even the combination of natural products and traditional drugs shows more vigorous anticancer activity and lower toxic and side effects than single chemotherapeutic drugs and targeted drug treatments. The application of Chinese herbal medicine with permanent history and economic benefits to cancer treatment, including lung cancer, may also bring new opportunities and challenges to cancer treatment. If traditional Chinese medicine can effectively reduce the cost of cancer treatment, improve the effect of cancer treatment, and apply it to the clinic, the cancer cure rate in China and even the world may be effectively controlled.

The multicomponent, multitarget, and multipathway characteristics of the active ingredients of traditional Chinese medicine also cast a veil of mystery on the study of the biological activity of conventional Chinese medicine monomers. In the future, we need to separate and extract effective small molecule compounds from traditional Chinese medicine by different scientific means so as to apply them to the treatment of tumors. There are still many challenges to overcome in clinical treatment. However, it is undeniable that in exploring new anticancer drugs, the combination of natural anticancer active ingredients of traditional Chinese medicine combined with chemotherapy and targeted therapy may become a unique choice for the treatment of patients with NSCLC.

Data Availability

The data used to support this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Heng Sun and Lijia Zhang contributed equally.

Acknowledgments

This paper was funded by the Heilongjiang Applied Technology Research and Development Project named “Based on the academic thought of Professor Duan Fujin, a master of Chinese medicine, on the treatment of gastrointestinal toxic and side effects after radiotherapy and chemotherapy for lung cancer with spleen deficiency” (no. GA19C109), Exploration on the operation mode of “one body and two wings” of provincial TCM tumor diagnosis and treatment center (no. 2020GSP07), Clinical observation of Zhen wu decoction plus diolong combined with cisplatin in the treatment of malignant pleural effusion (no. 2019MS07), and Effect of Zhen wu decoction plus diolong combined with cisplatin on the levels of IL-17 and VEGF in the treatment of malignant pleural effusion (no. ZHY2020-109).

References

Evidence-Based Complementary and Alternative Medicine

10 Evidence-Based Complementary and Alternative Medicine

10 Evidence-Based Complementary and Alternative Medicine

1. F. Rauchensteiner, Y. Matsumura, Y. Yamamoto, S. Yamaji, A. Banerjee, V. Banerjee, S. Czinn, and T. Blanchard, "In..." [51x749]


[99] I. L. Marostica, I. T. Silva, J. M. Kratz et al., “Synergistic antiproliferative effects of a new cucurbitacin B derivative


